Compare LNG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNG | NNVC |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7B | 24.2M |
| IPO Year | 1996 | 2008 |
| Metric | LNG | NNVC |
|---|---|---|
| Price | $280.30 | $0.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $290.33 | N/A |
| AVG Volume (30 Days) | ★ 3.8M | 233.0K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | ★ 69.93 | 10.00 |
| EPS | ★ 24.13 | N/A |
| Revenue | ★ $19,976,000,000.00 | N/A |
| Revenue This Year | $16.51 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | $11.67 | ★ N/A |
| Revenue Growth | ★ 27.21 | N/A |
| 52 Week Low | $186.20 | $0.85 |
| 52 Week High | $300.94 | $2.23 |
| Indicator | LNG | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 43.47 |
| Support Level | $219.20 | $0.85 |
| Resistance Level | $299.49 | $1.07 |
| Average True Range (ATR) | 11.11 | 0.06 |
| MACD | -1.25 | -0.01 |
| Stochastic Oscillator | 62.53 | 17.23 |
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.